Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab Deruxtecan”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04644068
What this trial is testing

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Who this might be right for
Ovarian CancerBreast CancerPancreatic Cancer+10 more
AstraZeneca 702
Testing effectiveness (Phase 2)Study completedNCT04539938
What this trial is testing

Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 70
Testing effectiveness (Phase 2)Looking for participantsNCT04553770
What this trial is testing

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast Cancer+4 more
Jonsson Comprehensive Cancer Center 88
Large-scale testing (Phase 3)Looking for participantsNCT06435429
What this trial is testing

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Who this might be right for
Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals 550
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07150208
What this trial is testing

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Who this might be right for
Breast Cancer With Brain MetastasisHER2-low Expressing Breast Cancer
Fudan University 140
Testing effectiveness (Phase 2)Study completedNCT04744831
What this trial is testing

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

Who this might be right for
Advanced Colorectal Cancer
Daiichi Sankyo 122
Testing effectiveness (Phase 2)Looking for participantsNCT07647016
What this trial is testing

Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study

Who this might be right for
Breast Cancer
Fudan University 53
Testing effectiveness (Phase 2)Looking for participantsNCT04616560
What this trial is testing

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Who this might be right for
Desmoplastic Small Round Cell TumorOsteosarcomaRecurrent Desmoplastic Small Round Cell Tumor+5 more
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Looking for participantsNCT07619521
What this trial is testing

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

Who this might be right for
Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage III Pancreatic Cancer AJCC v8+2 more
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Looking for participantsNCT06750484
What this trial is testing

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Who this might be right for
Breast Cancer Metastatic
Yale University 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07152782
What this trial is testing

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

Who this might be right for
Breast Cancer With Brain MetastasisHER2-positive Breast Cancer
Fudan University 202
Testing effectiveness (Phase 2)Active Not RecruitingNCT04379596
What this trial is testing

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Who this might be right for
Gastric Cancer
AstraZeneca 452
Testing effectiveness (Phase 2)Active Not RecruitingNCT06731803
What this trial is testing

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Who this might be right for
Esophagogastric Adenocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 36
Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Testing effectiveness (Phase 2)Looking for participantsNCT05824975
What this trial is testing

Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
GI Innovation, Inc. 358
Early research (Phase 1)Looking for participantsNCT06364410
What this trial is testing

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT05034887
What this trial is testing

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East 64
Large-scale testing (Phase 3)Looking for participantsNCT07022483
What this trial is testing

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Who this might be right for
Endometrial Cancer
Daiichi Sankyo 710
Testing effectiveness (Phase 2)Active Not RecruitingNCT05480384
What this trial is testing

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Who this might be right for
Esophageal AdenocarcinomaEsophageal CancerHER-2 Protein Overexpression+1 more
Brown University 1
Testing effectiveness (Phase 2)Study completedNCT04420598
What this trial is testing

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

Who this might be right for
Advanced Breast CancerHER2-positive Breast CancerBrain Metastases+1 more
MedSIR 41
Next Page